First patient enrolled in Phase II BG-12 combination trial
First patient enrolled in Phase II BG-12 combination trial
Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS).
The trial, called EXPLORE, will evaluate the safety and tolerability of BG-12 when administered with beta interferons (IFNB) or glatiramer acetate (GA) to patients who continue to have evidence of disease activity despite receiving consistent monotherapy for at least a year. Efficacy endpoints will also be assessed in a subset of patients. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2030 Views
-
Last post by NHE
-
- 0 Replies
- 10620 Views
-
Last post by NHE
-
- 0 Replies
- 1101 Views
-
Last post by frodo
-
- 0 Replies
- 1455 Views
-
Last post by NHE
-
- 2 Replies
- 3849 Views
-
Last post by DIM
-
- 1 Replies
- 2700 Views
-
Last post by Tif
-
- 0 Replies
- 2191 Views
-
Last post by NHE
-
- 0 Replies
- 2171 Views
-
Last post by NHE
-
- 0 Replies
- 10242 Views
-
Last post by NHE